Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

A. X. Zhu; R. S. Finn; P. R. Galle; J. M. Llovet; J. F. Blanc; T. Okusaka; I. Chau; D. Cella; A. Girvan; J. Gable; L. Bowman; Y. Hsu; P. B. Abada; M. Kudo

doi:10.1093/annonc/mdy282.006

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

A. X. Zhu, R. S. Finn, P. R. Galle, J. M. Llovet, J. F. Blanc, T. Okusaka, I. Chau, D. Cella, A. Girvan, J. Gable, L. Bowman, Y. Hsu, P. B. Abada, M. Kudo

Medical Social Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii208
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy282.006
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy282.006

Cite this

Zhu, A. X., Finn, R. S., Galle, P. R., Llovet, J. M., Blanc, J. F., Okusaka, T., Chau, I., Cella, D., Girvan, A., Gable, J., Bowman, L., Hsu, Y., Abada, P. B., & Kudo, M. (2018). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii208. https://doi.org/10.1093/annonc/mdy282.006

Zhu, A. X. ; Finn, R. S. ; Galle, P. R. et al. / Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib : Patient reported outcome results across two phase III studies (REACH-2 and REACH). In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii208.

@article{dab2b460243448d9861bfb292c3ac3b9,

title = "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)",

author = "Zhu, {A. X.} and Finn, {R. S.} and Galle, {P. R.} and Llovet, {J. M.} and Blanc, {J. F.} and T. Okusaka and I. Chau and D. Cella and A. Girvan and J. Gable and L. Bowman and Y. Hsu and Abada, {P. B.} and M. Kudo",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy282.006",

language = "English (US)",

volume = "29",

pages = "viii208",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

Zhu, AX, Finn, RS, Galle, PR, Llovet, JM, Blanc, JF, Okusaka, T, Chau, I, Cella, D, Girvan, A, Gable, J, Bowman, L, Hsu, Y, Abada, PB & Kudo, M 2018, 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii208. https://doi.org/10.1093/annonc/mdy282.006

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). / Zhu, A. X.; Finn, R. S.; Galle, P. R. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii208.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib

T2 - Patient reported outcome results across two phase III studies (REACH-2 and REACH)

AU - Zhu, A. X.

AU - Finn, R. S.

AU - Galle, P. R.

AU - Llovet, J. M.

AU - Blanc, J. F.

AU - Okusaka, T.

AU - Chau, I.

AU - Cella, D.

AU - Girvan, A.

AU - Gable, J.

AU - Bowman, L.

AU - Hsu, Y.

AU - Abada, P. B.

AU - Kudo, M.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85063194999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063194999&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy282.006

DO - 10.1093/annonc/mdy282.006

M3 - Article

C2 - 32136434

SN - 0923-7534

VL - 29

SP - viii208

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Zhu AX, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii208. doi: 10.1093/annonc/mdy282.006

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this